HRS-5965 tablets

DRUG2 trials

Sponsors

Chengdu Suncadia Medicine Co., Ltd.

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Phase 2

Proof of Concept Study to Assess the Efficacy, Safety of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria

CompletedNCT06051357

Chengdu Suncadia Medicine Co., Ltd.Paroxysmal Nocturnal Hemoglobinuria

Start: 2023-11-15End: 2024-03-25Updated: 2024-10-15

Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria

Active, not recruitingNCT06238544

Chengdu Suncadia Medicine Co., Ltd.Paroxysmal Nocturnal Hemoglobinuria

Start: 2024-02-06End: 2027-12-31Updated: 2025-12-24

Related Papers

Efficacy and Safety of HRS-5965 Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Have Not Received Complement Inhibitors: A Proof-of-Concept, Multicenter, Randomized, Open-Label Study

Blood2024-11-05